explore -WSS

explore

author：comprehensive 2025-09-30 01:02:25 - browse：29752

A screen at the New York Stock Exchange last November. Michael M. Santiago/Getty Images

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline.

The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.) It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030.

That matters because small molecules are more vulnerable to generic competition and the Medicare price negotiation introduced by the IRA. Suneet Varma, the commercial president of Pfizer’s oncology unit, said “this planned shift to biologics is expected to support the accelerated growth in both the top and bottom line,” referring to the revenue and profit lines of a balance sheet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Coercive sterilizations revealed by STAT prompt outrage

knowledge

WSS

Readout Newsletter: Merck, Vertex, and Viking updates

Oprah kicked off a national conversation on obesity. Let's have it

Teladoc has a new CEO, but challenges remain the same

There's no autism epidemic. It's an autism diagnosis epidemic

Eliminate the waiting period for sterilization covered by Medicaid

Oprah kicked off a national conversation on obesity. Let's have it

Wikipedia

explore

knowledge

23andMe had bad news about my health. I wish a person had delivered it

Steward Health Care has deal to sell doctor network to UnitedHealth

Activists slam private health insurers over coverage restrictions

California wildfire smoke linked to 52,000 early deaths, study says

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Eliminate the waiting period for sterilization covered by Medicaid

Novavax promises a turnaround & Lilly roils the obesity market

There's no autism epidemic. It's an autism diagnosis epidemic

Walensky prepares to leave CDC — and Congress — behind

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

entertainment

Cigna wins case to block Amy Bricker's move to CVS

Patient advocates debate FDA's accelerated approval process

Patient advocates debate FDA's accelerated approval process

Merck drug for rare lung condition set for approval in U.S.

Food as medicine: Medically tailored meals may get standardized

Moderna says combo Covid

hotspot

knowledge

knowledge

hotspot